The New England Journal of Medicine

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery

Retrieved on: 
Tuesday, October 17, 2023
Oncology, Health, FDA, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Congress, III, Hepatitis, HIV disease progression rates, Immunosuppression, MRK, NYSE, Lung cancer, Food, Platinum, American Joint Committee on Cancer, Pembrolizumab, The New England Journal of Medicine, AJCC, OS, PD-L1, Colitis, EGFR, Stanford University, Medicine, Pemetrexed, Patient, ESMO, Merck & Co., Steroid, EFS, II, Carboplatin, TPS, Pneumonitis, Paclitaxel, History, Head, International Association, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Society for Medical Oncology, Neoplasm, Hematopoietic stem cell transplantation, European Society of Gynaecological Oncology, T2A, ALK, Nephritis, Pharmaceutical industry, Vaccine, NSCLC, Merck

With this approval, KEYTRUDA has six indications in NSCLC, across both metastatic and earlier stages of NSCLC.

Key Points: 
  • With this approval, KEYTRUDA has six indications in NSCLC, across both metastatic and earlier stages of NSCLC.
  • The EFS results, which were from the first interim analysis, were published in June 2023 in the New England Journal of Medicine.
  • Adverse reactions occurring in patients with resectable NSCLC receiving KEYTRUDA in combination with platinum-containing chemotherapy, given as neoadjuvant treatment and continued as single agent adjuvant treatment, were generally similar to those occurring in patients across tumor types receiving KEYTRUDA in combination with chemotherapy.
  • Eighty-one percent of patients in the KEYTRUDA in combination with platinum-containing chemotherapy arm had definitive surgery compared to 76% of patients in the placebo in combination with platinum-containing chemotherapy arm.

Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board

Retrieved on: 
Thursday, October 5, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Aurora, Histology, Chinese University of Hong Kong, Multimedia, Science, Lung cancer, Biomarker, Chinese, University, Cedars-Sinai Medical Center, CLDN1, Abstract, Lung transplantation, The New England Journal of Medicine, AACR, Anesthesiology, Clinical Oncology, Clarivate, Long Island Jewish Medical Center, Book, Coronavirus Scientific Advisory Board, IPF, Respiratory therapist, University of the Witwatersrand School of Chemical and Metallurgical Engineering, Food and Drug Administration, Lung, US Food Sovereignty Alliance, Medical director, Patient, Idiopathic pulmonary fibrosis, AstraZeneca, ESMO, Therapy, Article, Publication, Long Island, ASCO, Pulmonary hypertension, CSCO, Research, Inova Fairfax Hospital, Pharmaceutical industry, Medical device, Vaccine

Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board.

Key Points: 
  • Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20231005193827/en/
    Lung experts Prof. Steven Nathan and Prof. Tony Mok join Alentis Therapeutics' Scientific Advisory Board.
  • (Photo: Alentis Therapeutics)
    “Tony and Steven have exceptional expertise in lung cancer and lung fibrosis, respectively, which will be of great value to our Scientific Advisory Board,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis.
  • Prof. Steven Nathan is the Medical Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital and is a Professor at the University of Virginia.

Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics

Retrieved on: 
Friday, October 13, 2023
Mount Sinai, Icahn School of Medicine at Mount Sinai, Contract research organization, Internal medicine, MS, Abstract, Research, VARSITY, The New England Journal of Medicine, Crohn's and Colitis Canada, Therapy, IBD, Safety, University, Inflammatory bowel disease, Annals of Internal Medicine, JAMA, Inflammatory Bowel Diseases, Publication, United States Army Medical Research and Development Command, Dean, Patient, Pharmaceutical industry, MD, Nature, Medicine, Lancet

LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.

Key Points: 
  • LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
  • The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
  • Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
  • He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics

Retrieved on: 
Friday, October 13, 2023
Mount Sinai, Icahn School of Medicine at Mount Sinai, Contract research organization, Internal medicine, MS, Abstract, Research, VARSITY, The New England Journal of Medicine, Crohn's and Colitis Canada, Therapy, IBD, Safety, University, Inflammatory bowel disease, Annals of Internal Medicine, JAMA, Inflammatory Bowel Diseases, Publication, United States Army Medical Research and Development Command, Dean, Patient, Pharmaceutical industry, MD, Nature, Medicine, Lancet

LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.

Key Points: 
  • LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
  • The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
  • Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
  • He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

She Did it!! Ultra Marathon Swimmer Sarah Thomas Completes Swim Across Lake Mead Swimming 47.5 Miles to Make Waves to Fight Cancer for Swim Across America

Retrieved on: 
Tuesday, October 10, 2023
Johns Hopkins University, SAA, UCSF Benioff Children's Hospital, Multimedia, Golden Gate Bridge, Health care, Memorial Sloan Kettering Cancer Center, Hope, Isle, Swimming, Breast cancer, Dostarlimab, The New England Journal of Medicine, Seattle Cancer Care Alliance, Beauty, North Channel (Great Britain and Ireland), GSK plc, Atlantic Ocean, Swim Across America, UCSF, Weill Cornell Medicine, Hoover Dam, Cancer, Sound, Record, Patient, FDA, Movement, Nantucket Cottage Hospital, Immunotherapy, Clinical trial, Volunteering, English, Research, Children's Hospital Oakland Research Institute, Breast Cancer Awareness Month, Water, Hotel, Dentistry, Quarry, Birth control, Lake Mead, Pembrolizumab

LAS VEGAS, Oct. 10, 2023 /PRNewswire-PRWeb/ -- On October 7, 2023, ultra marathon swimmer Sarah Thomas set another world record with a monumental swim that no other swimmer has ever attempted. Sarah completed a 47.5-mile swim (pending ratification) of the entire length of Lake Mead – from the Colorado River to the Hoover Dam. The swim took her 26 hours, 45 minutes and 45 seconds (26:45:45) to complete. Sarah, a breast cancer survivor, took on this swim not just to break another world record, but to help make waves in the fight against cancer and to raise critical funds for cancer research with Swim Across America.

Key Points: 
  • Sarah completed a 47.5-mile swim (pending ratification) of the entire length of Lake Mead – from the Colorado River to the Hoover Dam.
  • I'm a cold water swimmer, so this was a bit warmer than I'm used to, but it ended up being lovely," said Sarah Thomas.
  • I'm so excited to be able to accomplish swimming in Lake Mead, and as a breast cancer survivor, to do it during Breast Cancer Awareness Month, all while raising crucial funds for cancer research with Swim Across America."
  • Sarah has supported Swim Across America since 2018, when the inaugural Swim Across America - Denver swim was held in her home community.

Sage Growth Partners Releases New Patient Safety Report Providing Cross-Sector Insights from Hospitals, Health Systems, Non-Profit Organizations and Technology Companies

Retrieved on: 
Tuesday, October 3, 2023
Plague, BS, Doctor of Pharmacy, SGP, Friends, Marketing, Medicine, Cone Health Women's Hospital, The New England Journal of Medicine, MBA, BSN, Associate, Organization, Hospital, Patient safety, Perceptual Objective Listening Quality Analysis, Internal medicine, Institute for Safe Medication Practices, Mass General Brigham, RN, CPPS, Patient, HCA Healthcare, MHA, BCPP, Safety, FRCA, Pharmaceutical industry, Nursing, Brigham, MD

BALTIMORE, October 3, 2023 /PRNewswire/ -- Sage Growth Partners (SGP), a nationally recognized healthcare research, strategy, and marketing firm, has released a new cross-sector safety report that provides perspectives on hospital patient safety challenges, improvement opportunities and how healthcare organizations can best advance positive changes.

Key Points: 
  • BALTIMORE, October 3, 2023 /PRNewswire/ -- Sage Growth Partners (SGP), a nationally recognized healthcare research, strategy, and marketing firm, has released a new cross-sector safety report that provides perspectives on hospital patient safety challenges, improvement opportunities and how healthcare organizations can best advance positive changes.
  • The new report, Leading Through Change: Because Patients Deserve More , offers insights from industry leaders within hospitals, health systems, non-profit organizations, and technology companies.
  • Key insights and dialogue points of the report, include:
    What is the biggest patient safety gain that has occurred in the past decade?
  • While these conversations have revealed that most hospitals are prioritizing patient safety improvements, safety errors and adverse events continue to plague even the best organizations.

U.S. Centers for Disease Control and Prevention Selects Verily to Support National Wastewater Monitoring

Retrieved on: 
Monday, October 2, 2023
Health, Infectious Diseases, Environment, Health Technology, Sustainability, COVID-19, Emory University, The New England Journal of Medicine, Centers for Disease Control and Prevention, SARS-CoV-2, Public, California Department, Infection, Stanford University, Doctor of Philosophy, CDC, MPXV, California Department of Public Health, Monkeypox virus, Public health, Verily, MD, Letter, NWSS, Vaccine

Verily, an Alphabet precision health technology company, today announced it was selected by the Centers for Disease Control (CDC) to support the agency’s National Wastewater Surveillance System (NWSS).

Key Points: 
  • Verily, an Alphabet precision health technology company, today announced it was selected by the Centers for Disease Control (CDC) to support the agency’s National Wastewater Surveillance System (NWSS).
  • The CDC launched NWSS in September 2020 to coordinate and build the nation’s capacity to track the presence of SARS-CoV-2 in wastewater samples collected across the country.
  • Verily’s Wastewater program offers wastewater surveillance to test for pathogens present in wastewater treatment facilities nationwide, allowing for timely detection and monitoring to inform public health actions.
  • Verily’s Wastewater program provides a robust measure of community infection trends at the height of surges when clinical testing can have insufficient capacity.

TATAA Biocenter appoints Johanna Nilsson as new Head of Marketing to strengthen scientific communication and client engagement

Retrieved on: 
Monday, October 2, 2023
The New England Journal of Medicine, Heart, Communication, University, Publication, Doctor of Philosophy, TATAA, Head, University of Gothenburg, AstraZeneca, Fine chemical, Pharmaceutical industry, Neurology, Marketing

GOTHENBURG, Sweden, Oct. 2, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, is pleased to announce the appointment of Johanna Nilsson as Head of Marketing.

Key Points: 
  • GOTHENBURG, Sweden, Oct. 2, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, is pleased to announce the appointment of Johanna Nilsson as Head of Marketing.
  • "By appointing Johanna Nilsson as Head of Marketing, we gain a key member of the management team with a unique set of experiences from a wide range of positions in the biotech industry.
  • Johanna Nilsson brings seven years of comprehensive marketing experience, ranging from strategic planning to implementation.
  • "It's an honor to join TATAA as Head of Marketing.

TATAA Biocenter appoints Johanna Nilsson as new Head of Marketing to strengthen scientific communication and client engagement

Retrieved on: 
Monday, October 2, 2023
The New England Journal of Medicine, Heart, Communication, University, Publication, Doctor of Philosophy, TATAA, Head, University of Gothenburg, AstraZeneca, Fine chemical, Pharmaceutical industry, Neurology, Marketing

GOTHENBURG, Sweden, Oct. 2, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, is pleased to announce the appointment of Johanna Nilsson as Head of Marketing.

Key Points: 
  • GOTHENBURG, Sweden, Oct. 2, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, is pleased to announce the appointment of Johanna Nilsson as Head of Marketing.
  • "By appointing Johanna Nilsson as Head of Marketing, we gain a key member of the management team with a unique set of experiences from a wide range of positions in the biotech industry.
  • Johanna Nilsson brings seven years of comprehensive marketing experience, ranging from strategic planning to implementation.
  • "It's an honor to join TATAA as Head of Marketing.

Ultra Marathon Swimmer Sarah Thomas Will Attempt 50-Mile Swim in Lake Mead from Colorado River to the Hoover Dam and Make Waves to Fight Cancer with Swim Across America

Retrieved on: 
Thursday, September 28, 2023
Golden Gate Bridge, Dostarlimab, Volunteering, GSK plc, English, Sound, North Channel (Great Britain and Ireland), Health care, The New England Journal of Medicine, Johns Hopkins University, Clinical trial, Seattle Cancer Care Alliance, Cancer, SAA, Record, Hope, UCSF Benioff Children's Hospital, Research, Multimedia, Immunotherapy, Movement, Beauty, Patient, UCSF, Nantucket Cottage Hospital, Water, Atlantic Ocean, Memorial Sloan Kettering Cancer Center, Isle, Swim Across America, Hoover Dam, Weill Cornell Medicine, FDA, Children's Hospital Oakland Research Institute, Breast cancer, Hotel, Dentistry, Birth control, Dam, Pharmaceutical industry, Lake Mead, Pembrolizumab

LAS VEGAS, Sept. 28, 2023 /PRNewswire-PRWeb/ -- On October 6, 2023, ultra marathon swimmer Sarah Thomas will attempt to set another world record with a monumental swim that no other swimmer has ever attempted. Sarah will set out to complete a 50-mile swim of the entire length of Lake Mead – from the Colorado River to the Hoover Dam. She estimates the swim will take her 30 hours to complete. Sarah, a breast cancer survivor, is undertaking this swim not just to break another world record, but to help make waves in the fight against cancer and to raise critical funds for cancer research with Swim Across America.

Key Points: 
  • Sarah will set out to complete a 50-mile swim of the entire length of Lake Mead – from the Colorado River to the Hoover Dam.
  • Sarah already holds a long list of record-breaking feats and hopes to add the Lake Mead swim to her list.
  • "After my first visit to the Hoover Dam in February 2021, I knew I had to swim across Lake Mead," said Sarah.
  • Sarah's swim across Lake Mead will start in South Cove, where her favorite river, The Colorado, enters the lake.